Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Neuroendocrine 1

Interventions

pembrolizumab 565 Specimen Handling 494 Carboplatin 452 Magnetic Resonance Spectroscopy 444 Cyclophosphamide 421 Cisplatin 405 Radiotherapy 352 Bevacizumab 316 Gemcitabine 313 Paclitaxel 299 Biopsy 290 Drug Therapy 284 Blood Specimen Collection 249 Capecitabine 246 fludarabine 241 Oxaliplatin 241 Nivolumab 235 venetoclax 220 Injections 213 Docetaxel 211 Fluorouracil 206 Dexamethasone 187 Radiosurgery 182 Standard of Care 160 Rituximab 159 Pemetrexed 156 Surgical Procedures, Operative 149 atezolizumab 146 durvalumab 145 Leucovorin 140

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × DLL3 protein, human × Clear all

NCT06893783 2026-04-13

DeLLight

Asan Medical Center

Phase 2 Recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡